| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | marinopyrrole A | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |